A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease

Table 2 Risk of study outcomes comparing clarithormycin users versus nonusers

	Overall mortality			Cardiovascular mortality			Cardiovascular morbidity
	Event	Incidence rate per 1000 patient-years	Adjusted HR* (95% CI)	Event	Incidence rate per 1000 patient-years	Adjusted HR* (95% CI)	Event	Incidence rate per 1000 patient-years	Adjusted HR^# (95% CI)
Nonusers (n = 4070)	399	21.2	1 (reference)	33	1.8	1 (reference)	360	20.2	1 (reference)
Clarithormycin users (n = 4070)	395	21.5	1.08 (0.93–1.24)	28	1.5	0.95 (0.57–1.59)	341	19.6	0.94 (0.89–1.09)

HR hazard ratio, CI confidence interval
*Adjusted for all covariates (age per year, sex, comorbidity, Charlson comorbidity index, number of medical visits, and drugs use) listed in Table 1
^#Adjusted for all covariates (age per year, sex, comorbidity, Charlson comorbidity index, number of medical visits, and drugs use) listed in Table 1 and competing mortality

ISSN: 1471-230X